MHMartijn W. F. VAN Den Hoogen

Martijn W. F. VAN Den Hoogen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martijn W. F. VAN Den Hoogen has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Martin J. Hoogduijn

    Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands

    4 shared publications
  • Robert C. Minnee

    Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands

    4 shared publications
  • Jeroen de Jonge

    Department of Surgery, Division of Hepato-Pancreato-Biliary and Transplant Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands

    3 shared publications
  • Luuk Hilbrands

    Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands

    3 shared publications
  • Carla C. Baan

    Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; and

    2 shared publications
  • Dennis A. Hesselink

    Erasmus MC Transplant Institute, University Medical Center Rotterdam, Department of Internal Medicine, Rotterdam, the Netherlands

    2 shared publications

Latest Publications

  • Open Access

    Delivering hospital care at home in a Dutch Tertiary University Hospital: protocol for a prospective feasibility cohort study evaluating a Virtual Ward for early discharge of inpatients

    by Michael C van Herwerden, Niels T B Scholte, Argisjt Mkrtchjan, Lida Feyz, Arien P Mol, Jessie Aitken, Rudolf A de Boer, Prewesh P Chandoesing, Diederik A M P J Gommers, Britt De Haan, et al.

    Introduction Virtual Wards (VWs) facilitate hospital-level monitoring, diagnostics and treatment within patients’ homes, while the hospital team retains responsibility for care. International research indicates that VWs decrease hospital length of stay without increasing readmissions; however, the feasibility and key operational determinants within Dutch care remain uncertain. This protocol outlines the VW for Early Discharge in Patients Receiving Inpatient Care (VIP Care) study. Methods and analysis The VIP Care study is a single-centre prospective feasibility cohort study conducted at Erasmus University Medical Center (Erasmus MC), Rotterdam, the Netherlands. The study encompasses seven predefined subcohorts with n=51 eligible patients per subcohort: (1) bacterial, fungal or parasitic infections; (2) viral respiratory infections; (3) dehydration; (4) decompensated heart failure; (5) high-dose corticosteroid treatment; (6) post-transsphenoidal pituitary surgery follow-up and (7) severe inflammatory skin disease with or without bacterial or viral superinfection. Adults who require hospital-level monitoring and/or therapy may qualify for early discharge to the VW. The VW integrates scheduled, patient-performed measurements using (European Conformity) CE-marked devices with structured symptom assessment submitted via a patient application, and data review in an electronic health record-integrated clinician cockpit. Submissions are evaluated by VW tele-nurses using prespecified Early Warning Score based thresholds and an escalation protocol. Patients receive a daily physician telephone review. Diagnostics and treatments are administered at home to hospital standards through established home-care services. The primary outcome (feasibility) is adherence to transfer, defined as the proportion of eligible inpatients who provide written informed consent and are subsequently successfully transferred to the VW. The prespecified feasibility threshold is 30%. Secondary outcomes include reach (eligibility, invitation and consent rates among admitted patients), operational performance during the VW episode (alert frequency and handling, contact volumes and actions), length of stay on the ward and in the VW, emergency department reassessments and 30-day readmissions. Qualitative interviews will be conducted to identify implementation determinants. Ethics and dissemination The study received approval from the Erasmus MC Medical Ethics Committee (MEC-2024–0060; amendment MEC-2024–0060 A0001). Incremental risk is considered minimal. Written informed consent is obtained. Findings will be disseminated through peer-reviewed publications, conference presentations and an accessible lay summary. Trial registration number ClinicalTrials.gov NCT06936891; CCMO NL85516.078.24. Recruitment began in May 2025 and is ongoing.

  • Open Access

    Normothermic versus hypothermic machine perfusion in kidney transplantation: A randomized controlled trial

    by Julia S. Slagter, Sarah Bouari, Elsaline Rijkse, Iacopo Cristoferi, Yitian Fang, Agni Papamanoli, Andrew Stubbs, Jeroen de Jonge, Ron W.F. de Bruin, Martijn W.F. van Den Hoogen, et al.


  • Open Access

    Trained immunity suppression determines kidney allograft survival

    by Inge Jonkman, Maaike M.E. Jacobs, Yutaka Negishi, Cansu Yanginlar, Joost H.A. Martens, Marijke Baltissen, Michiel Vermeulen, Martijn W.F. van Den Hoogen, Marije Baas, Johan van der Vlag, et al.


  • Endothelial Cell Replacement of Human Veins, Modeling Vascular Repair and Endothelial Cell Chimerism

    by Hector Tejeda-Mora, Yvette Den Hartog, Ivo J. Schurink, Monique M.A. Verstegen, Jeroen de Jonge, Martijn W.F. van Den Hoogen, Carla C. Baan, Robert C. Minnee, Martin J. Hoogduijn, Luc J.W. van der Laan, et al.

    Allogeneic transplant organs are potentially highly immunogeneic. The endothelial cells (EC) located within the vascular system serve as the primary interface between the recipient’s immune system and the donor organ, playing a key role in the allo-immune response. In this study, we investigated the potential use of recipient-derived ECs in a vein recellularization model. Here, human iliac veins underwent complete decellularization using a triton X-100 protocol. We demonstrated the feasibility of re-endothelializing acellular blood vessels using either HUVEC or human venous-derived ECs, with this re-endothelization being sustainable for up to 28 days in vitro. The re-endothelialized veins exhibited the restoration of vascular barrier function, along with the restoration of innate immune regulatory capabilities, evident through the facilitation of monocytic cell transmigration and their polarization towards a macrophage phenotype following trans-endothelial extravasation. Finally, we explored whether recellularization with EC of a different donor could prevent antibody-mediated rejection. We demonstrated that in chimeric vessels, allogeneic EC became a target of the humoral anti-donor response after activation of the classical immune complement pathway whereas autologous EC were spared, emphasizing their potential utility prior to transplantation. In conclusion, our study demonstrates that replacement of EC in transplants could reduce the immunological challenges associated with allogeneic grafts.


  • Open Access

    Telemedicine for Kidney Transplant Recipients: Current State, Advantages, and Barriers

    by Bartu Msc Hezer, Emma K. Massey, Marlies E.J. Reinders, Mirjam Tielen, Jacqueline van de Wetering, Dennis A. Hesselink, Martijn W.F. van Den Hoogen

    Telemedicine is defined as the use of electronic information and communication technologies to provide and support healthcare at a distance. In kidney transplantation, telemedicine is limited but is expected to grow markedly in the coming y. Current experience shows that it is possible to provide transplant care at a distance, with benefits for patients like reduced travel time and costs, better adherence to medication and appointment visits, more self-sufficiency, and more reliable blood pressure values. However, multiple barriers in different areas need to be overcome for successful implementation, such as recipients’ preferences, willingness, skills, and digital literacy. Moreover, in many countries, limited digital infrastructure, legislation, local policy, costs, and reimbursement issues could be barriers to the implementation of telemedicine. Finally, telemedicine changes the way transplant professionals provide care, and this transition needs time, training, willingness, and acceptance. This review discusses the current state and benefits of telemedicine in kidney transplantation, with the aforementioned barriers, and provides an overview of future directions on telemedicine in kidney transplantation. Export


  • Open Access

    Care for the organ transplant recipient on the intensive care unit

    by M.W.F. van Den Hoogen, L. Seghers, O.C. Manintveld, S. Roest, J.A. Bekkers, C.M. Den Hoed, R.C. Minnee, H.R.H. de Geus, R.J. van Thiel, D.A. Hesselink


  • Open Access

    Circulating endothelial cells transiently increase in peripheral blood after kidney transplantation

    by H. Tejeda-Mora, J. G. H. P. Verhoeven, W. Verschoor, K. Boer, D. A. Hesselink, M. W. F. van Den Hoogen, L. J. W. van der Laan, C. C. Baan, R. C. Minnee, M. J. Hoogduijn

    The diagnosis of kidney allograft rejection is based on late histological and clinical markers. Early, specific and minimally-invasive biomarkers may improve rejection diagnosis. Endothelial cells (EC) are one of the earliest targets in kidney transplant rejection. We investigated whether circulating EC (cEC) could serve as an earlier and less invasive biomarker for allograft rejection. Blood was collected from a cohort of 51 kidney transplant recipients before and at multiple timepoints after transplantation, including during a for cause biopsy. The number and phenotype of EC was assessed by flow-cytometric analysis. Unbiased selection of EC was done using principal component (PCA) analysis. Paired analysis revealed a transient cEC increase of 2.1-fold on the third day post-transplant, recovering to preoperative levels at seventh day post-transplant and onwards. Analysis of HLA subtype demonstrated that cEC mainly originate from the recipient. cEC levels were not associated with allograft rejection, allograft function or other allograft pathologies. However, cEC in patients with allograft rejection and increased levels of cEC showed elevated levels of KIM-1 (kidney injury marker-1). These findings indicate that cEC numbers and phenotype are affected after kidney transplantation but may not improve rejection diagnosis.


  • Open Access

    Additional Normothermic Machine Perfusion Versus Hypothermic Machine Perfusion in Suboptimal Donor Kidney Transplantation: Protocol of a Randomized, Controlled, Open-Label Trial

    by Elsaline Rijkse, Sarah Bouari, Hendrikus J. A. N. Kimenai, Jeroen DE Jonge, Ron W. F. DE Bruin, Julia S. Slagter, Martijn W. F. VAN Den Hoogen, Jan N. M. Ijzermans, Martin J. Hoogduijn, Robert C. Minnee

    : Introduction: Ageing of the general population has led to an increase in the use of suboptimal kidneys from expanded criteria donation after brain death (ECD-DBD) and donation after circulatory death (DCD) donors. However, these kidneys have inferior graft outcomes and lower rates of immediate function. Normothermic machine perfusion (NMP) may improve outcomes of these suboptimal donor kidneys. Previous non-randomized studies have shown the safety of this technique and suggested its efficacy in improving the proportion of immediate functioning kidneys compared to static cold storage (SCS). However, its additional value to hypothermic machine perfusion (HMP), which has already been proved superior to SCS, has not yet been established. Methods and analysis: This single-center, open-label, randomized controlled trial aims to assess immediate kidney function after 120 minutes additional, end-ischemic NMP compared to HMP alone. Immediate kidney function is defined as no dialysis treatment in the first week after transplant. Eighty recipients on dialysis at the time of transplant who receive an ECD-DBD or DCD kidney graft are eligible for inclusion. In the NMP group, the donor kidney is taken of HMP upon arrival in the recipient hospital and thereafter put on NMP for 120 minutes at 37 degrees Celsius followed by transplantation. In the control group, donor kidneys stay on HMP until transplantation. The primary outcome is immediate kidney function. Ethics and dissemination: The protocol has been approved by the Medical Ethical Committee of Erasmus Medical Center (2020-0366). Results of this study will be submitted to peer-reviewed journals. Registration: registered in clinicaltrials.gov (NCT04882254). Highlights:


  • Open Access

    Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients

    by Marieke van der Zwan, Dennis A. Hesselink, Esther Brusse, Pieter A. van Doorn, Martijn W.F. van Den Hoogen, Annelies E. de Weerd, Bart C. Jacobs


  • Open Access

    Rituximab as Induction Therapy After Renal Transplantation: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety

    by M. W. F. van Den Hoogen, E. G. Kamburova, M. C. Baas, E. J. Steenbergen, S. Florquin, H. J. P. M. Koenen, I. Joosten, L. B. Hilbrands